Hansoh Pharmac Hd 00001 Stock Price To Earning

3KY Stock  EUR 2.16  0.06  2.70%   
HANSOH PHARMAC HD 00001 fundamentals help investors to digest information that contributes to HANSOH PHARMAC's financial success or failures. It also enables traders to predict the movement of HANSOH Stock. The fundamental analysis module provides a way to measure HANSOH PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HANSOH PHARMAC stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

HANSOH PHARMAC HD 00001 Company Price To Earning Analysis

HANSOH PHARMAC's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

 = 

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Current HANSOH PHARMAC Price To Earning

    
  38.60 X  
Most of HANSOH PHARMAC's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HANSOH PHARMAC HD 00001 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition

Based on the latest financial disclosure, HANSOH PHARMAC HD 00001 has a Price To Earning of 38.6 times. This is 49.38% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The price to earning for all Germany stocks is 34.4% lower than that of the firm.

HANSOH Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HANSOH PHARMAC's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HANSOH PHARMAC could also be used in its relative valuation, which is a method of valuing HANSOH PHARMAC by comparing valuation metrics of similar companies.
HANSOH PHARMAC is rated second in price to earning category among its peers.

HANSOH Fundamentals

About HANSOH PHARMAC Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze HANSOH PHARMAC HD 00001's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HANSOH PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HANSOH PHARMAC HD 00001 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in HANSOH Stock

HANSOH PHARMAC financial ratios help investors to determine whether HANSOH Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HANSOH with respect to the benefits of owning HANSOH PHARMAC security.